LFD 200
Alternative Names: LFD-200Latest Information Update: 26 Oct 2025
At a glance
- Originator Lifordi Immunotherapeutics
- Class Anti-inflammatories; Antirheumatics; Drug conjugates; Glucocorticoids; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 26 Oct 2025 Lifordi Immunotherapeutics has patent protection for composition of matter on LFD-200, VISTA ADCs and therapeutic uses, complementarity-determining regions for anti-VISTA antibody/other related antibodies, linker/payload designs, and more
- 06 Oct 2025 Preclinical trials in Autoimmune disorders in USA (SC) prior to September 2024
- 06 Oct 2025 Lifordi Immunotherapeutics plans a phase-I trial for Rheumatoid arthritis (In volunteers) in Australia, Georgia, Moldova, Poland, and Ukraine (SC), (NCT07207954)